RU2418792C2 - Азольные соединения с нейтротерапевтической активностью - Google Patents

Азольные соединения с нейтротерапевтической активностью Download PDF

Info

Publication number
RU2418792C2
RU2418792C2 RU2007143073/04A RU2007143073A RU2418792C2 RU 2418792 C2 RU2418792 C2 RU 2418792C2 RU 2007143073/04 A RU2007143073/04 A RU 2007143073/04A RU 2007143073 A RU2007143073 A RU 2007143073A RU 2418792 C2 RU2418792 C2 RU 2418792C2
Authority
RU
Russia
Prior art keywords
azole compound
halogen
hydrogen
group
enantiomer
Prior art date
Application number
RU2007143073/04A
Other languages
English (en)
Russian (ru)
Other versions
RU2007143073A (ru
Inventor
Ёнг-Мун ЧОИ (US)
Ёнг-Мун ЧОИ
Чун-Гил КИМ (KR)
Чун-Гил КИМ
Янг-Сан КАНГ (KR)
Янг-Сан КАНГ
Хан-Джу ЙИ (KR)
Хан-Джу ЙИ
Хиан-Сеок ЛИ (KR)
Хиан-Сеок ЛИ
Бон-Чул КУ (KR)
Бон-Чул КУ
Юн-Хо ЛИ (KR)
Юн-Хо ЛИ
Дае-Джунг ИМ (KR)
Дае-Джунг ИМ
Ю-Джин ШИН (KR)
Ю-Джин ШИН
Original Assignee
Ск Холдингс Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37115369&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2418792(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ск Холдингс Ко., Лтд. filed Critical Ск Холдингс Ко., Лтд.
Publication of RU2007143073A publication Critical patent/RU2007143073A/ru
Application granted granted Critical
Publication of RU2418792C2 publication Critical patent/RU2418792C2/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D257/00Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04Five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41921,2,3-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/041,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
RU2007143073/04A 2005-04-22 2006-04-21 Азольные соединения с нейтротерапевтической активностью RU2418792C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67453005P 2005-04-22 2005-04-22
US60/674,530 2005-04-22

Publications (2)

Publication Number Publication Date
RU2007143073A RU2007143073A (ru) 2009-05-27
RU2418792C2 true RU2418792C2 (ru) 2011-05-20

Family

ID=37115369

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2007143073/04A RU2418792C2 (ru) 2005-04-22 2006-04-21 Азольные соединения с нейтротерапевтической активностью

Country Status (23)

Country Link
US (1) US7598279B2 (https=)
EP (1) EP1879873B1 (https=)
JP (1) JP5035238B2 (https=)
KR (1) KR101286499B1 (https=)
CN (1) CN101228138B (https=)
AR (1) AR053065A1 (https=)
AU (1) AU2006237798B2 (https=)
BE (1) BE2021C524I2 (https=)
BR (1) BRPI0607529B8 (https=)
CA (1) CA2606258C (https=)
DK (1) DK1879873T3 (https=)
ES (1) ES2441765T3 (https=)
FI (1) FIC20210018I1 (https=)
FR (1) FR21C1027I2 (https=)
MX (1) MX2007013197A (https=)
MY (1) MY148589A (https=)
NL (1) NL301106I2 (https=)
PL (1) PL1879873T3 (https=)
PT (1) PT1879873E (https=)
RU (1) RU2418792C2 (https=)
TW (1) TWI398249B (https=)
WO (1) WO2006112685A1 (https=)
ZA (1) ZA200709994B (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2688673C2 (ru) * 2014-02-28 2019-05-22 ЭсКей БАЙОФАРМАСЬЮТИКАЛЗ КО., ЛТД. Аминокарбонилкарбаматные соединения
RU2790360C2 (ru) * 2014-02-28 2023-02-17 ЭсКей БАЙОФАРМАСЬЮТИКАЛЗ КО., ЛТД. Аминокарбонилкарбаматные соединения

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7598279B2 (en) 2005-04-22 2009-10-06 Sk Holdings Co., Ltd. Neurotherapeutic azole compounds
ES2379848T3 (es) * 2007-05-14 2012-05-04 Sk Biopharmaceuticals Co., Ltd. Compuesto arilpiperazina arilalcanoil carbomoiloxi novedoso, composiciones farmacéuticas que comprenden el compuesto y método para tratar el dolor, ansiedad y depresión al administrar el compuesto
AU2008258599B2 (en) 2007-06-05 2013-06-13 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission
EP2285787B1 (en) * 2008-06-05 2015-08-26 SK Biopharmaceuticals Co., Ltd. 3-substituted propanamine compounds
WO2010150946A1 (en) * 2009-06-22 2010-12-29 Sk Holdings Co., Ltd. Method for preparation of carbamic acid (r)-1-aryl-2-tetrazolyl-ethyl ester
US8404461B2 (en) * 2009-10-15 2013-03-26 SK Biopharmaceutical Co. Ltd. Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester
EP2496227B1 (en) 2009-11-06 2019-05-22 SK Biopharmaceuticals Co., Ltd. Methods for treating fibromyalgia syndrome
BR112012010670A2 (pt) 2009-11-06 2016-04-12 Sk Biopharmaceuticals Co Ltd métodos para tratamento de distúrbio de défict de atenção/hiperatividade
US8623913B2 (en) 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
AU2013202982C1 (en) * 2012-01-06 2017-01-05 Novartis Ag Heterocyclic compounds and methods for their use
US9630896B2 (en) 2013-11-22 2017-04-25 Tansna Therapeutics, Inc. 2,5-dialkyl-4-H/halo/ether-phenol compounds
ITUA20161941A1 (it) * 2016-03-23 2017-09-23 Univ Degli Studi Di Siena Uso di derivati dell’acido 2-amminotiofen-3- carbossilico per il trattamento delle dipendenze da cibo
KR102421013B1 (ko) * 2016-05-19 2022-07-14 에스케이바이오팜 주식회사 삼차신경통을 예방 또는 치료하기 위한 카바메이트 화합물의 용도
KR102421006B1 (ko) * 2016-05-19 2022-07-14 에스케이바이오팜 주식회사 두통의 예방학적 치료를 위한 카바메이트 화합물의 용도
KR102489052B1 (ko) * 2016-05-19 2023-01-16 에스케이바이오팜 주식회사 섬유근육통 또는 섬유근육통의 연관된 기능적 증후군을 예방 또는 치료하기 위한 카바메이트 화합물의 용도
EP3556365B1 (en) * 2016-12-14 2025-07-02 SK Biopharmaceuticals Co., Ltd. Use of carbamate compound for prevention, alleviation, or treatment of demyelinating disease
US11033531B2 (en) * 2016-12-14 2021-06-15 Sk Biopharmaceuticals Co., Ltd. Use of carbamate compound for preventing, alleviating, or treating tremors or tremor syndrome
KR102901908B1 (ko) * 2016-12-14 2025-12-17 에스케이바이오팜 주식회사 운동신경세포 질환의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도
MX2019006940A (es) * 2016-12-14 2019-09-06 Sk Biopharmaceuticals Co Ltd Uso de compuestos de carbamato para prevencion, alivio o tratamiento del trastorno bipolar.
ES2898457T3 (es) * 2016-12-14 2022-03-07 Sk Biopharmaceuticals Co Ltd Comprimido de disgregación oral que comprende un compuesto de carbamato
CA3046458A1 (en) 2016-12-14 2018-06-21 Sk Biopharmaceuticals Co., Ltd. Parenteral liquid preparation comprising carbamate compound
EP3556363B1 (en) * 2016-12-14 2024-03-06 SK Biopharmaceuticals Co., Ltd. Use of carbamate compound for prevention, alleviation or treatment of pruritus
KR102900173B1 (ko) * 2016-12-14 2025-12-12 에스케이바이오팜 주식회사 조현병, 강박장애 및 투렛증후군으로부터 선택되는 정신증 장애의 예방, 경감 또는 치료에 있어서의 카바메이트 화합물의 용도
WO2019098633A1 (ko) * 2017-11-14 2019-05-23 에스케이바이오팜 주식회사 내장통 또는 내장 질환에서 기인한 통증을 예방, 경감 또는 치료하기 위한 카바메이트 화합물의 용도
MX2020004975A (es) * 2017-11-14 2020-08-24 Sk Biopharmaceuticals Co Ltd Mezcla que contiene compuesto de carbamato para prevencion, mitigacion o tratamiento de esquizofrenia.
AU2018370164B2 (en) * 2017-11-14 2024-08-15 Sk Biopharmaceuticals Co., Ltd. Use of carbamate compound for reducing or treating developmental disorders including fragile X syndrome, Angelman syndrome or Rett syndrome
US11389429B2 (en) 2017-11-14 2022-07-19 Sk Biopharmaceuticals Co., Ltd. Use of carbamate compound for preventing, alleviating or treating myotonia
PT3711758T (pt) * 2017-11-14 2024-04-22 Sk Biopharmaceuticals Co Ltd Utilização de composto de carbamato para prevenir, aliviar ou tratar crise de ausência ou epilepsia que apresenta crise de ausência
EP3711760B1 (en) 2017-11-14 2024-02-14 SK Biopharmaceuticals Co., Ltd. Use of carbamate compound for preventing or treating diseases associated with increase in late sodium current
TWI826531B (zh) * 2018-09-21 2023-12-21 南韓商愛思開生物製藥股份有限公司 具有㗁二唑之化合物及包含該化合物之醫藥組合物
ES2978226T3 (es) * 2018-09-21 2024-09-09 Sk Biopharmaceuticals Co Ltd Compuesto de carbamato y uso de la formulación que lo comprende para prevenir, aliviar o tratar el trastorno de estrés agudo o el trastorno de estrés postraumático
EP3854392A4 (en) * 2018-09-21 2022-08-17 SK Biopharmaceuticals Co., Ltd. USE OF A CARBAMATE COMPOUND TO PREVENT, RELIEVE OR TREAT CONJUNCTING SEIGES
AU2019361856B2 (en) * 2018-10-19 2024-11-07 Sk Biopharmaceuticals Co., Ltd. Use of carbamate compound for preventing, alleviating or treating diabetic peripheral neuropathy or chemotherapy-induced peripheral neuropathy
US10611737B1 (en) 2019-10-24 2020-04-07 Sk Biopharmaceuticals Co., Ltd. Method for preparing aryl 2-tetrazol-2-yl ketone with improved selectivity
BR112022009533A2 (pt) * 2019-11-22 2022-08-02 Sk Biopharmaceuticals Co Ltd Composição farmacêutica para administração oral, e, método para preparar uma composição farmacêutica
US20230338295A1 (en) * 2020-08-06 2023-10-26 Sk Biopharmaceuticals Co., Ltd. Solid oral composition comprising carbamate compound, and preparation method therefor
CN114317620B (zh) * 2020-09-29 2024-02-02 上海医药工业研究院 一种(r)-2-(2-氯苯基)环氧乙烷的生物制备方法
AR125970A1 (es) 2021-05-28 2023-08-30 Sk Biopharmaceuticals Co Ltd Formulaciones de suspensión acuosa para administración oral que comprenden un compuesto de carbamato
CN115974799B (zh) * 2021-10-14 2024-08-13 成都百裕制药股份有限公司 氨基甲酸酯取代的醇衍生物及其在医药上的应用
ES2931000B2 (es) * 2022-07-14 2023-07-07 Univ Madrid Complutense Proceso para la preparación de cenobamato
CN115716810B (zh) * 2022-11-15 2026-02-13 江苏艾立康医药科技有限公司 一种西诺氨酯的晶体形式及其制备方法
CN118239901A (zh) * 2023-03-15 2024-06-25 江苏恩华药业股份有限公司 一种氨基甲酸(r)-1-(2-氯苯基)-2-四唑-2-基乙酯的晶体

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3415840A (en) * 1965-10-22 1968-12-10 American Home Prod Pyrazole-1-ethanol derivatives
RU2117664C1 (ru) * 1991-08-22 1998-08-20 Варнер-Ламберт Компани Производные тетразолсодержащего амида, смесь их изомеров, отдельные изомеры или фармацевтически приемлемые соли

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK181988A (da) * 1988-03-30 1989-10-01 Dumex Ltd As Thiocarbamidsyreester til brug som terapeutikum samt praeparat til behandling af alkoholmisbrug
EP1406605B1 (en) * 2001-06-25 2007-09-19 SK Corporation Carbamates of 2-heterocyclic-1,2-ethanediols
US6770659B2 (en) * 2002-08-26 2004-08-03 Sk Corporation Benzoyl piperidine compounds
US7598279B2 (en) 2005-04-22 2009-10-06 Sk Holdings Co., Ltd. Neurotherapeutic azole compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3415840A (en) * 1965-10-22 1968-12-10 American Home Prod Pyrazole-1-ethanol derivatives
RU2117664C1 (ru) * 1991-08-22 1998-08-20 Варнер-Ламберт Компани Производные тетразолсодержащего амида, смесь их изомеров, отдельные изомеры или фармацевтически приемлемые соли

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2688673C2 (ru) * 2014-02-28 2019-05-22 ЭсКей БАЙОФАРМАСЬЮТИКАЛЗ КО., ЛТД. Аминокарбонилкарбаматные соединения
RU2790360C2 (ru) * 2014-02-28 2023-02-17 ЭсКей БАЙОФАРМАСЬЮТИКАЛЗ КО., ЛТД. Аминокарбонилкарбаматные соединения
RU2793742C2 (ru) * 2017-11-14 2023-04-05 ЭсКей БАЙОФАРМАСЬЮТИКАЛЗ КО., ЛТД. Применение карбаматного соединения для снижения или лечения нарушений развития, включая синдром хрупкой x-хромосомы, синдром ангельмана или синдром ретта
RU2796295C2 (ru) * 2018-09-21 2023-05-22 ЭсКей БАЙОФАРМАСЬЮТИКАЛЗ КО., ЛТД. Карбаматное соединение и применение включающей его композиции для профилактики, облегчения или лечения острого стрессового расстройства или посттравматического стрессового расстройства

Also Published As

Publication number Publication date
CN101228138A (zh) 2008-07-23
FIC20210018I1 (fi) 2021-06-14
MX2007013197A (es) 2008-02-12
TW200722085A (en) 2007-06-16
BE2021C524I2 (https=) 2025-12-10
AU2006237798A1 (en) 2006-10-26
NL301106I2 (nl) 2021-08-03
FR21C1027I1 (fr) 2021-08-27
JP2008538557A (ja) 2008-10-30
RU2007143073A (ru) 2009-05-27
ZA200709994B (en) 2008-11-26
PL1879873T3 (pl) 2014-03-31
US7598279B2 (en) 2009-10-06
EP1879873B1 (en) 2013-10-09
AU2006237798B2 (en) 2012-07-12
BRPI0607529B1 (pt) 2021-05-18
PT1879873E (pt) 2014-01-03
BRPI0607529B8 (pt) 2021-05-25
EP1879873A4 (en) 2011-06-15
EP1879873A1 (en) 2008-01-23
DK1879873T3 (da) 2013-12-09
JP5035238B2 (ja) 2012-09-26
FR21C1027I2 (fr) 2022-06-03
CA2606258A1 (en) 2006-10-26
CA2606258C (en) 2014-01-14
KR20080005437A (ko) 2008-01-11
MY148589A (en) 2013-05-15
AR053065A1 (es) 2007-04-18
BRPI0607529A2 (pt) 2009-09-15
KR101286499B1 (ko) 2013-07-16
CN101228138B (zh) 2012-11-21
WO2006112685A1 (en) 2006-10-26
TWI398249B (zh) 2013-06-11
US20060258718A1 (en) 2006-11-16
NL301106I1 (nl) 2021-06-02
ES2441765T3 (es) 2014-02-06

Similar Documents

Publication Publication Date Title
RU2418792C2 (ru) Азольные соединения с нейтротерапевтической активностью
RU2339618C2 (ru) Новые обратные агонисты рецептора св1
US20060211761A1 (en) Hmg-coa-reductase inhibitors
RU2356893C2 (ru) Ингибиторы фосфодиэстеразы 4
RU2403247C2 (ru) Модуляторы никотиновых ацетилхолиновых рецепторов альфа 7 и их терапевтические применения
RU2012123154A (ru) Способы лечения синдрома фибромиалгии
RU2389722C2 (ru) Варианты имидазола в качестве модуляторов рецептора гамма-аминомасляной кислоты (gaba) для лечения желудочно-кишечных (жк) расстройств
RU2434853C2 (ru) Новые конденсированные производные пиррола
RU2342383C2 (ru) ПРОИЗВОДНЫЕ ИМИДАЗОЛ-4-ИЛЭТИНИЛПИРИДИНА, СПОСОБ ИХ ПОЛУЧЕНИЯ (ВАРИАНТЫ) И ПРИМЕНЕНИЕ В КАЧЕСТВЕ АНКСИОЛИТИКА, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ ЛЕЧЕНИЯ НАРУШЕНИЙ, ОПОСРЕДУЕМЫХ РЕЦЕПТОРОМ mGLuR5
Disadee et al. Chirality Transfer from Guanidinium Ylides to 3-Alkenyl (or 3-Alkynyl) Aziridine-2-carboxylates and Application to the Syntheses of (2 R, 3 S)-3-Hydroxyleucinate and d-e rythro-Sphingosine
MA31466B1 (fr) Derives de benzimidazole
ATE362931T1 (de) 8-azabicyclo(3.2.1)oct-2en-derivate, deren herstellung und anwendung
NZ592836A (en) Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders
JP2005508293A5 (https=)
RU2007140737A (ru) Пиразолы
RU2394031C2 (ru) Соли четвертичного аммония в качестве антагонистов м3
Angle et al. New Access to Indolizidine and Pyrrolizidine Alkaloids from an Enantiopure Proline: Total Syntheses of (−)-Lentiginosine and (1 R, 2 R, 7a R)-Dihydroxypyrrolizidine
ATE403426T1 (de) Opioid-rezeptor-aktive 4-(3-hydroxyphenyl) oder 4-(3-alkoxyphenyl)-1,2,4-triazol-verbindungen
RU2401267C2 (ru) Замещенные производные бензохинолизина
MA27781A1 (fr) 3-fluoro-piperidines comme antagonistes de nmda/nr2b.
EA200600879A1 (ru) Тетразольные производные и способы лечения расстройств, связанных с метаболизмом, с их помощью
CA2433039A1 (en) Agent for therapeutic and prophylactic treatment of neuropathic pain
RU2009146132A (ru) Карбамоилоксиарилалканоиларилпиперазиновое соединение, фармацевтические композиции, содержащие его, и способ лечения боли, беспокойства и депрессии
PE20050440A1 (es) Derivados de n-heterociclo sustituidos para modificar la recaptacion de monoaminas
RU2380367C2 (ru) Пиррол- или имидазоламиды для лечения ожирения

Legal Events

Date Code Title Description
PC41 Official registration of the transfer of exclusive right

Effective date: 20120524